搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

  1. 首頁
  2. 試劑盒
  3. 酶聯(lián)免疫試劑盒
  4. Human Fibroblast growth factor 19(FGF19) ELISA kit

Human Fibroblast growth factor 19(FGF19) ELISA kit

  • 中文名稱：
    人成纖維細(xì)胞生長(zhǎng)因子19(FGF19)酶聯(lián)免疫試劑盒
  • 貨號(hào)：
    CSB-EL008624HU
  • 規(guī)格：
    96T/48T
  • 價(jià)格：
    ￥3600/￥2500
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    人成纖維細(xì)胞生長(zhǎng)因子19(FGF19)酶聯(lián)免疫試劑盒（CSB-EL008624HU）為雙抗夾心法ELISA試劑盒，定量檢測(cè)血清、血漿、組織勻漿樣本中的FGF19含量。FGF19是一種成纖維細(xì)胞生長(zhǎng)因子，在肝臟表達(dá)可調(diào)控膽汁酸合成等代謝過程。研究機(jī)制方面，它與FGFR4等受體結(jié)合，激活下游信號(hào)通路，參與調(diào)節(jié)血糖、脂質(zhì)代謝等。對(duì)它的研究有望為代謝性疾病等的治療提供新靶點(diǎn)和策略。試劑盒檢測(cè)范圍為25 pg/mL-1600 pg/mL，靈敏度為6.25 pg/mL。適用于科研實(shí)驗(yàn)中探究FGF19在代謝調(diào)控、疾病模型中的表達(dá)變化，或評(píng)估藥物干預(yù)對(duì)FGF19信號(hào)通路的影響；可為細(xì)胞生物學(xué)、分子機(jī)制研究及靶向藥物開發(fā)等基礎(chǔ)科研領(lǐng)域提供可靠的數(shù)據(jù)支持。本品僅用于科研，不用于臨床診斷，產(chǎn)品具體參數(shù)及操作步驟詳見產(chǎn)品說明書。
  • 別名：
    FGF 19 ELISA Kit; FGF-19 ELISA Kit; FGF15 ELISA Kit; FGF19 ELISA Kit; FGF19_HUMAN ELISA Kit; Fibroblast growth factor 15 ELISA Kit; Fibroblast growth factor 19 ELISA Kit
  • 縮寫：
  • Uniprot No.：
  • 種屬：
    Homo sapiens (Human)
  • 樣本類型：
    serum, plasma, tissue homogenates
  • 檢測(cè)范圍：
    25 pg/mL-1600 pg/mL
  • 靈敏度：
    6.25 pg/mL
  • 反應(yīng)時(shí)間：
    1-5h
  • 樣本體積：
    50-100ul
  • 檢測(cè)波長(zhǎng)：
    450 nm
  • 研究領(lǐng)域：
    Signal Transduction
  • 測(cè)定原理：
    quantitative
  • 測(cè)定方法：
    Sandwich
  • 精密度：
    Intra-assay Precision (Precision within an assay): CV%<8%        
    Three samples of known concentration were tested twenty times on one plate to assess.    
    Inter-assay Precision (Precision between assays): CV%<10%        
    Three samples of known concentration were tested in twenty assays to assess.      
                   
  • 線性度：
    To assess the linearity of the assay, samples were spiked with high concentrations of human FGF19 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.  
    　 Sample Serum(n=4)    
    1:1 Average % 92    
    Range % 87-99    
    1:2 Average % 103    
    Range % 99-104    
    1:4 Average % 93    
    Range % 87-98    
    1:8 Average % 91    
    Range % 89-97    
  • 回收率：
    The recovery of human FGF19 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.  
     
    Sample Type Average % Recovery Range    
    Serum (n=5) 95 92-99    
    EDTA plasma (n=4) 90 86-93    
                   
                   
  • 標(biāo)準(zhǔn)曲線：
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.  
     
    pg/ml OD1 OD2 Average Corrected    
    1600 1.911 1.989 1.950 1.815    
    800 1.323 1.321 1.322 1.187    
    400 0.992 0.954 0.973 0.838    
    200 0.700 0.686 0.693 0.558    
    100 0.542 0.569 0.556 0.421    
    50 0.358 0.336 0.347 0.212    
    25 0.262 0.244 0.253 0.118    
    0 0.133 0.136 0.135 　    
  • 數(shù)據(jù)處理：
  • 貨期：
    3-5 working days

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

  • 功能：
    Involved in the suppression of bile acid biosynthesis through down-regulation of CYP7A1 expression, following positive regulation of the JNK and ERK1/2 cascades. Stimulates glucose uptake in adipocytes. Activity requires the presence of KLB and FGFR4.
  • 基因功能參考文獻(xiàn)：
    1. Study showed that FGF19 amplification is a genetic event in Chinese lung squamous cell carcinoma (LSCC) patients, with a frequency of 37.5%. FGF19 amplified LSCC cells express relatively higher levels of FGF19 mRNA expression, and downregulation of FGF19 expression can induce significant cell killing effects in vitro and in vivo. PMID: 28906590
    2. FGFR4/FGF19 autocrine signaling mediates the survival of a subset of basal-like breast cancer cells PMID: 27192118
    3. FGF19 copy number may increase in hepatocellular carcinoma accompanying a complete response to sorafenib treatment PMID: 27384874
    4. Study demonstrates that elevated FGF19 expression or hyperactivation of FGF19/FGFR4 signaling in hepatocellular carcinoma cells is one of the main mechanisms of sorafenib resistance. PMID: 28069043
    5. This is the first study to elucidate FGF19/FGFR4 signaling in favor of hepatocellular carcinoma cells developing from fatty liver PMID: 27447573
    6. High expression of FGF19 is associated with hepatocellular carcinoma. PMID: 26498355
    7. Findings show that FGF19 provides a cytoprotective role against ER stress by activating a FGFR4-GSK3beta-Nrf2 signaling cascade, suggesting targeting this signaling node as a candidate therapeutic regimen for hepatocellular carcinoma (HCC) management. PMID: 28951455
    8. Fibroblast growth factor 19 levels in human portal blood are higher than in arterial blood. Fibroblast growth factor 19 is released by the portal-drained viscera under fasted steady state conditions. PMID: 28003563
    9. Intestinal sensing of highly elevated levels of conjugated bile acids in blood promotes FGF15/FGF19 signaling, reducing hepatic bile acid synthesis and modulating bile acid transporters. PMID: 28498614
    10. serum FGF19 and FGF21 and hepatic Klotho expression are inversely associated with hepatic damage in children with NAFLD PMID: 23840612
    11. Administering FGF19, or suitable mimetic, as a pharmacological intervention to increase circulating levels of FGF19 and suppress BA synthesis by inhibiting CYP7A1 gene expression is likely to provide therapeutic benefits for many PBC patients PMID: 28570655
    12. Amplification of FGF19 was validated in independent LSCC samples. Furthermore, FGF19 stimulated LSCC cell growth in vitro. These data implicate FGF19 as a potential driver gene in LSCC with clinic characteristics as smoking. PMID: 26943773
    13. FGF19 is able to enhance migration and invasion abilities of gastric cancer cells. PMID: 27053348
    14. Bile acid and FGF19 levels increased after Roux-en-Y bypass, but not after intensive medial management in type 2 diabetic subjects who achieved similar improvement in glycemic control. PMID: 26259981
    15. FGF19 correlates with severity of liver disease and can potentially serve as an indicator of chronic cholestatic liver injury. PMID: 26293907
    16. Study shows that FGF19 can be secreted and promotes ovarian cancer progression such as proliferation and invasion by activating FGFR4. PMID: 26323668
    17. we suggest that considerable mechanistic differences exist between humans and mice with regard to the nuclear receptors controlling the VitA-FGF15/19 axis. PMID: 26723851
    18. Suggest a potential connection between gallbladder cholangiocyte-derived FGF19 and bile acid metabolism that could lead to metabolic dysregulation following cholecystectomy. PMID: 26256900
    19. discusses current knowledge of the complex biology of the endocrine FGFs. PMID: 26567701
    20. FGF-19 increment after OGL was positively associated with age, and negatively associated with abnormal glucose regulation and statin treatment PMID: 26343925
    21. KL methylation is a characteristic of many breast cancer cases . However, the resulting or associated perturbation in FGFR4 expression, similar to FGF19, could be utilized as a biomarker for poor prognosis PMID: 26152288
    22. The pathogenesis of intestinal failure associated liver disease is uncertain, we therefore investigated the role of FGF19 and pro-inflammatory cytokines has on this disease state. PMID: 25595885
    23. In this review, we have reported the altered expression of FGF19 in non-alcoholic fatty liver disease and hepatocellular carcinoma; we find limited information on the role of FGF19 in other liver diseases PMID: 25547779
    24. In mice with humanized livers, expression of an FGF19 transgene corrects bile acid signaling defects, resulting in normalization of bile acid synthesis, the bile acid pool, and liver size. PMID: 26028580
    25. The data suggest that FGF19/FGF21 circulating levels and hepatic gene expression of the associated signaling pathway are significantly dysregulated in type 2 diabetes. PMID: 25664662
    26. Describe a nontumorigenic FGF19 variant, M70, which regulates bile acid metabolism and, through inhibition of bile acid synthesis/reduction of excess hepatic bile acid accumulation, protects mice from cholestatic liver injury. PMID: 25080475
    27. obesity appears as the predominant determinant of the abnormalities in FGF21 and FGF19 levels. Opposite changes in beta-Klotho expression in fat and liver indicate potential tissue-specific alterations in the responsiveness to endocrine FGFs in obesity PMID: 24813368
    28. FGF19 levels were reduced in non-diabetic obese subjects as compared to lean controls and obese type 2 diabetic subjects. PMID: 24841294
    29. Fibroblast growth factor 19 might be associated with biochemical recurrence after radical prostatectomy by promoting cell proliferation and epithelial-mesenchymal transition of prostate cancer PMID: 25854696
    30. In hepatocellular carcinoma, FGF19 amplifications, known to activate Wnt signaling, were mutually exclusive with CTNNB1 and AXIN1 mutations, and significantly associated with cirrhosis. PMID: 24798001
    31. FGF19 expression is not associated with lymph node metastasis and locally invasive characteristics of the tumor in colorectal cancers PMID: 23803094
    32. Reduced fibroblast growth factor 19 is a feature of bile acid diarrhea. PMID: 23981126
    33. [review] While FGF19 is a negative feedback regulator of bile acid metabolism and can circulate as a hormone, emerging evidence has showed its autocrine or exocrine function. PMID: 24827712
    34. FGF19 stimulates tumor progression by activating the STAT3 pathway. PMID: 24728076
    35. Reduced serum FGF19 levels could be involved in the pathophysiology of gestational diabetes mellitus, while increased serum FGF21 levels could be a compensatory response to this disease. PMID: 24260557
    36. Quantification of FGF19 expression appears to provide valuable prognostic information in breast cancer PMID: 24248542
    37. Fasting serum FGF19 levels were decreased in Chinese subjects with IFG and inversely associated with fasting glucose levels. PMID: 23628619
    38. These results suggest that SREBP-2 negatively regulates the FXR-mediated transcriptional activation of the FGF19 gene in human intestinal cells. PMID: 24321096
    39. Serum FGF19 is associated with the presence and severity of coronary artery disease in a Chinese population. PMID: 23940810
    40. The specificity of hFGF19 signaling is greatly altered in a mouse model system. PMID: 23064887
    41. FGF19 protein expression might be an effective predictor of early recurrence and a marker for poor prognosis of hepatocellular carcinoma. PMID: 23456506
    42. FGF19 (fibroblast growth factor 19) as a novel target gene for activating transcription factor 4 in response to endoplasmic reticulum stress PMID: 23205607
    43. A decrease in fasting FGF19 levels is associated with the development of non-alcoholic fatty liver disease in obese adolescents. PMID: 23329754
    44. HNF4alpha and LRH-1 promote active transcription histone marks on the Cyp7a1 promoter that are reversed by FGF19 in a SHP-dependent manner PMID: 23038264
    45. These results suggest that FGF19 is transcriptionally activated through multiple Farnesoid X receptor-responsive elements in the promoter region PMID: 22561792
    46. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PMID: 22442730
    47. The FGF19 effect on APOA was attenuated by transfection of primary hepatocytes with siRNA against the FGF19 receptor 4 (FGFR4). PMID: 22267484
    48. Baseline serum FGF-19 levels are significantly lower in obese patients with type 2 diabetes and is at least partially dependent upon nutritional status, but is not related to glucose metabolism or insulin sensitivity parameters. PMID: 21574752
    49. Mouse Fgf15 and human FGF19 play key roles in enterohepatic signaling, regulation of liver bile acid biosynthesis, gallbladder motility and metabolic homeostasis PMID: 22396169
    50. FGF-19 levels are low in type 2 diabetic patients with metabolic syndrome. PMID: 22166511

    顯示更多

    收起更多

  • 亞細(xì)胞定位：
    Secreted.
  • 蛋白家族：
    Heparin-binding growth factors family
  • 組織特異性：
    Expressed in fetal brain, cartilage, retina, and adult gall bladder.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 3675

    OMIM: 603891

    KEGG: hsa:9965

    STRING: 9606.ENSP00000294312

    UniGene: Hs.249200